Related Experiment Video
Updated: Jan 24, 2026

Surgical Models of Gastroesophageal Reflux with Mice
Published on: August 25, 2015
Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design
Daniel Vt Catenacci1, Anteneh Tesfaye2, Mohamed Tejani3
1University of Chicago Comprehensive Cancer Center, Chicago, IL, USA.
Abstract:
Bemarituzumab is an afucosylated monoclonal antibody against FGFR2b (a FGF receptor) with demonstrated monotherapy clinical activity in patients with late-line gastric cancer whose tumors overexpress FGFR2b (NCT02318329). We describe the rationale and design of the FIGHT trial (NCT03343301), a global, randomized, double-blind, placebo-controlled Phase III study evaluating the role of bemarituzumab in patients with previously untreated, FGFR2b-overexpressing advanced gastroesophageal cancer. Patients are randomized in a blinded fashion to the combination of mFOLFOX6 and bemarituzumab or mFOLFOX6 and placebo. Eligible patients are selected based on the presence of either FGFR2b protein overexpression determined by immunohistochemistry or FGFR2 gene amplification determined by circulating tumor DNA. The primary end point is overall survival, and secondary end points include progression-free survival, objective response rate and safety.
Insights
Bemarituzumab shows promise in treating advanced gastroesophageal cancer by targeting FGFR2b. This study evaluates its efficacy when combined with chemotherapy in previously untreated patients.
Area of Science:
- Oncology
- Gastroenterology
- Immunotherapy
Background:
- Bemarituzumab, an afucosylated monoclonal antibody targeting FGFR2b, has shown clinical activity in late-line gastric cancer.
- FGFR2b overexpression is a targetable biomarker in advanced gastroesophageal cancer.
Purpose of the Study:
- To evaluate the efficacy and safety of bemarituzumab in combination with mFOLFOX6 chemotherapy.
- To assess bemarituzumab's role in previously untreated, FGFR2b-overexpressing advanced gastroesophageal cancer.
Main Methods:
- Global, randomized, double-blind, placebo-controlled Phase III trial (FIGHT trial).
- Patients randomized to mFOLFOX6 plus bemarituzumab or mFOLFOX6 plus placebo.
- Eligibility based on FGFR2b protein overexpression (immunohistochemistry) or FGFR2 gene amplification (circulating tumor DNA).
Main Results:
- Primary endpoint: Overall survival.
- Secondary endpoints: Progression-free survival, objective response rate, and safety.
Conclusions:
- The FIGHT trial aims to establish bemarituzumab as a new standard of care for FGFR2b-positive advanced gastroesophageal cancer.
- Results will inform future treatment strategies targeting FGFR2b in this patient population.
Related Concept Videos
Study Designs in Epidemiology
Observational studies are those where the researcher does not intervene but rather observes natural variations. They include cross-sectional, cohort, and...
Study Design in Statistics
Does aspirin reduce the risk of heart attacks? Is one brand of fertilizer more effective at growing roses than another? Is fatigue as dangerous to a driver as the influence of alcohol? Questions like these are answered using randomized experiments with proper...
Positive Regulator Molecules
Design Example: Identifying the Locations of Monuments in the Field Using Global Positioning System Device
Group Design
Imaging Studies III: Computed Tomography

